Regentis (RGNT) Director Jeff Dykan Receives 37,326 Options/Warrants

What Happened
Jeff Dykan, a director of Regentis Biomaterials Ltd. (RGNT), received two equity awards on July 9, 2026: 12,500 warrants and 24,826 stock options (total 37,326 derivative instruments). Both were reported as grants (transaction code A) at $0.00 cash consideration — these are derivative awards, not an immediate purchase of common stock. The warrants were board-approved on Feb 23, 2026 and became effective after shareholder approval on July 9, 2026; the options were board-approved May 28, 2026 and also received shareholder approval July 9, 2026.

Key Details

• Transaction date(s): July 9, 2026; Form 4 filed July 13, 2026 (filed on the required SEC deadline).
• Grants: 12,500 warrants (exercisable; three-year term) and 24,826 options (subject to vesting). Total granted = 37,326 derivative instruments. Reported acquisition price = $0.00 (no cash paid at grant).
• Vesting (options): Vest quarterly with 1/12 vesting on Aug 28, 2026, and one-twelfth on the last day of each subsequent three‑month period until fully vested on May 28, 2029; vesting requires continuous employment.
• Other footnotes: Warrants were board-approved Feb 23, 2026 (shareholder approval on July 9). To qualify for certain Israeli tax benefits, securities under the 2024 Share Option Plan must be registered in the name of a trustee.
• Shares owned after transaction: Not specified in this filing.
• Derivative note: These are warrants/options — Dykan must exercise them (and possibly pay an exercise price) to receive common shares; exercise price was not disclosed in this Form 4.

Context
Grants of options and warrants are common compensation/retention tools and do not represent an open‑market purchase or sale by the insider. Options vesting over three years align the award with future service; the exercisable warrants (three‑year term) could be converted earlier if the holder chooses and pays any applicable exercise price. These grants are informational rather than an immediate market signal.